Is MEDVi GLP-1 FDA Approved? Verified 2026 Status + FDA Letter
Last verified: May 16, 2026. Next review: June 2026.
The 60-Second Answer
No — MEDVi’s compounded GLP-1 medications are not FDA-approved.
MEDVi states this directly on its own site: compounded GLP-1s are produced in regulated facilities but “are not FDA-approved or evaluated for safety, efficacy, or quality.”
Brand-name drug products that contain semaglutide or tirzepatide — Wegovy®, Ozempic®, Zepbound®, Mounjaro® — are FDA-approved for specific labeled uses. MEDVi’s compounded versions are not FDA-approved finished drug products. Those are not the same thing.
Here’s what most reviews miss: MEDVi also has a brand-name path. Through a $99 membership, MEDVi can connect you with FDA-approved Wegovy or Zepbound at the brand-name medication’s full price. Same platform, two very different products.
So “Is MEDVi FDA-approved?” isn’t really one question. It’s two:
- Is MEDVi as a company FDA-approved? The FDA doesn’t approve companies. It approves specific drug products.
- Will the medication you receive be FDA-approved? That depends entirely on which path you pick.
And yes — the FDA sent MEDVi a warning letter on February 20, 2026 (#721455). It was about marketing claims that the FDA said implied FDA approval. MEDVi responded publicly in April 2026. We’ll walk through both sides below, plus what to verify before checkout, and which path actually fits you.
Quick Pick: Which Path Fits You?
| If this is your priority | The path that fits | Why |
|---|---|---|
| Lowest cash-pay monthly cost, comfortable with compounded | MEDVi compounded path ($179 first / $299 refill) | Lower-cost cash-pay option we verified, but the finished medication is not FDA-approved |
| FDA-approved finished medication, like the MEDVi platform | MEDVi brand-name path ($99 + Wegovy/Zepbound cost) | Real FDA-approved Wegovy or Zepbound through MEDVi's pharmacy partners |
| FDA-approved medication + help with insurance | Ro ($39 first / $149 ongoing) | Free Insurance Coverage Checker, FDA-approved Wegovy pill/pen, Zepbound KwikPen, and Foundayo |
| Still not sure | Take our 60-second match quiz | Personalized fit in under a minute |
Before you go further, pick your rule. Most readers fall into one of three buckets: “FDA-approved only,” “lowest cash-pay cost,” or “still figuring it out.”
Cash-pay. Verify medication type and cancellation window before checkout.
See what your insurance covers in under two minutes. No commitment.
No payment info. Personalized fit in under a minute.
Affiliate disclosure: We may earn a commission from some links on this page. That does not change FDA status, pricing, or what we publish.
The Rule That Clears Up Almost Every “Is X FDA-Approved?” Question
We call it the 3-bucket rule. Once it clicks, the rest of this page makes sense.
| Bucket | FDA status | MEDVi example |
|---|---|---|
| The telehealth platform | Not something the FDA approves at all | MEDVi (a website + clinician network + pharmacy referral) |
| A compounded medication | Not FDA-approved as a finished drug product | MEDVi compounded semaglutide / tirzepatide |
| A specific brand-name drug product | FDA-approved for specific labeled uses | Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo |
The FDA approves specific drug products, not platforms. And FDA-approved drug products are different from compounded versions — even when those compounded versions involve the same molecule.
Is MEDVi GLP-1 FDA Approved? (The Direct Answer)
No.
MEDVi’s compounded GLP-1 medications — compounded semaglutide and compounded tirzepatide, in injection or tablet form — are not FDA-approved. MEDVi states this directly on its own consumer-facing pages. That’s not us reading between the lines. That’s MEDVi’s own legal disclosure.
What “not FDA-approved” actually means (in plain English)
The FDA reviews specific finished drug products. Wegovy is one of those. It has been reviewed for:
- Safety at the doses sold
- Effectiveness for the labeled use
- Quality control in manufacturing
- Consistent strength and purity in every dose
When a compounding pharmacy makes its own version, that specific finished product has not gone through that review. Whether the compounded product contains the right active ingredient at the right strength, properly stored and labeled, depends entirely on the compounder’s practices — not on FDA pre-market approval.
The FDA has also warned that some compounded semaglutide products contain salt forms of semaglutide, which the FDA says are different active ingredients than the semaglutide in FDA-approved drugs. The FDA has said it is not aware of a lawful basis for using those salt forms in compounding.
So is MEDVi itself a real company?
Yes. MEDVi presents itself as a telehealth platform that doesn’t compound or dispense medication directly. MEDVi’s site says prescriptions are issued only after consultation with an independent licensed provider, and medical treatment is provided by CareGLP Affiliated P.C.s and OpenLoop Health. MEDVi lists US-licensed compounding pharmacy partners including Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding, while also stating MEDVi is not acting as a pharmacy and does not handle dispensing.
“Not FDA-approved” doesn’t mean “illegal” or “fake.” It means the medication itself didn’t go through the FDA’s pre-market approval process for the finished product. The question isn’t whether MEDVi is real. The question is whether the medication you’ll get matches what you actually want.
Cash-pay. Verify medication type and cancellation window before checkout.
What Part of MEDVi Is Not FDA-Approved?
The compounded path. That’s the cheaper one. Here’s what falls in this bucket, with MEDVi’s published starting prices:
| Option | First month | Refill price |
|---|---|---|
| Compounded semaglutide injection | $179 | $299 (verified on MEDVi GLP page) |
| Compounded tirzepatide injection | $349 (start) | Confirm at checkout |
| Compounded semaglutide tablet | $249 (start) | Confirm at checkout |
| Compounded tirzepatide tablet | $279 (start) | Confirm at checkout |
None of these are FDA-approved as finished products. Pricing verified on MEDVi pages May 16, 2026. Confirm exact ongoing pricing at checkout.
What is “compounded,” exactly?
Compounded medications are prepared by a pharmacy for a specific patient’s prescription. The federal compounding pathways under sections 503A and 503B exist for legitimate medical reasons — but FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.
That standard matters in 2026 more than it did in 2024. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025. Since those shortages ended, federal compounding for mass-marketed copies of these drugs has faced tighter restrictions.
April 30, 2026 FDA proposal
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comments are due June 29, 2026. If the proposal is finalized, the compounded GLP-1 supply pathway will narrow further.
Why the oral compounded path deserves extra scrutiny
Peptides like semaglutide and tirzepatide are large molecules that the stomach normally breaks down before they can be absorbed. Whether compounded oral tablets achieve clinically meaningful absorption without a specialized absorption enhancer is an open question.
A class-action complaint filed November 20, 2025 in the District of Delaware against OpenLoop Health Inc., Triad Rx Buyer LLC, and Triad Rx Inc. alleges compounded oral tirzepatide tablets had no demonstrated mechanism of absorption or efficacy. MEDVi is not named as a defendant in the docket, but Fierce Healthcare reported the named plaintiff alleged he purchased the pills through MEDVi. These are allegations in pending litigation, not findings. The case is unresolved. If you’re considering MEDVi’s oral path specifically, ask your prescriber what evidence supports absorption for the specific formulation.
What Part of MEDVi Is FDA-Approved? (The Path Most Reviews Miss)
MEDVi offers a brand-name path with FDA-approved Wegovy and Zepbound through a separate $99 membership.
Same MEDVi platform. Same clinicians. Different pharmacy fulfillment, different medication, completely different FDA status. The medication you get on the brand-name path is the same Wegovy or Zepbound you’d get at a Walgreens — manufactured by Novo Nordisk or Eli Lilly, FDA-approved for chronic weight management.
MEDVi’s brand-name path: the real numbers
| Brand-name option | What it is | MEDVi’s published price |
|---|---|---|
| Wegovy (semaglutide) | FDA-approved for chronic weight management & cardiovascular risk reduction | Brand-name medication cost + $99 membership |
| Zepbound (tirzepatide) | FDA-approved for chronic weight management & obstructive sleep apnea | Brand-name medication cost + $99 membership |
| Ozempic injection | FDA-approved for type 2 diabetes; sometimes prescribed off-label for weight loss | MEDVi lists Ozempic at $1,999/month |
All prices verified on MEDVi pages as of May 16, 2026. Verify current pricing at checkout.
MEDVi brand-name fits if:
- → You want a real FDA-approved finished drug product
- → You’re cash-pay or have HSA/FSA funds
- → You like MEDVi’s platform but want zero ambiguity on FDA status
MEDVi brand-name doesn’t fit if:
- → You need help getting insurance to cover Wegovy/Zepbound → Ro is better (free Insurance Coverage Checker)
- → You can’t afford $1,000+/month brand-name pricing
Cash-pay or HSA/FSA. Real FDA-approved brand-name medication. $99 membership + medication cost.
What Did the February 2026 FDA Warning Letter to MEDVi Say?
FDA Warning Letter #721455 — issued February 20, 2026
Addressee: MEDVi, LLC dba MEDVi. Source: FDA.gov public database.
What the FDA flagged
According to the letter posted on FDA.gov, the FDA reviewed website content at medvi.io in December 2025 and cited false or misleading claims. Two specific issues:
- The packaging in MEDVi’s product images had “MEDVi” on the label, suggesting MEDVi was the entity compounding the drug. The FDA said this was not accurate — MEDVi doesn’t compound. Its pharmacy partners do.
- Marketing language — specifically the phrases “Same active ingredient as Wegovy® and Ozempic®” and “Same active ingredient as Mounjaro® and Zepbound®” — implied, according to the FDA, that the compounded products had been FDA-approved or evaluated for safety and effectiveness when they had not been.
The FDA’s exact words:
“Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”
What the warning letter did not say
The letter did not directly allege contamination, patient harm, or a defective shipment. The cited violations were about marketing claims — not specific allegations of unsafe medication. That distinction matters. But it doesn’t make the underlying issue trivial.
The industry context most articles skip
MEDVi was not singled out. According to STAT News reporting, the FDA issued similar warning letters to more than 30 telehealth companies in February and March 2026 for the same kind of misbranding violations. Under the FDA’s own Regulatory Procedures Manual, warning letters are described as “informal and advisory” communications — not findings of guilt or legal judgments. As of May 16, 2026, no close-out letter has been published in the FDA’s public warning-letter database for MEDVi’s #721455.
MEDVi’s response (April 8, 2026)
MEDVi published a public communication addressing the warning letter on April 8, 2026. According to that statement, the warning letter referenced medvi.io (an older domain), not the primary medvi.org. MEDVi described the cited content as outdated affiliate marketing copy and said the material was removed. The statement also said: “My company MEDVi has never received a letter from the FDA.”
In fairness, the FDA’s publicly posted warning letter is addressed to “MEDVi, LLC dba MEDVi” — the legal entity behind both domains. Both statements are now part of the public record. You can weigh them yourself.
What this means for you specifically
Practically speaking, the warning letter is a signal — not a death sentence. If you decide to use MEDVi:
- Ask in writing which pharmacy will fill your prescription
- Confirm whether your medication is compounded or brand-name before you pay
- Verify the medication you receive matches the prescription you signed up for
- Know that the regulatory environment around compounded GLP-1s is changing fast
FDA-approved Wegovy, Zepbound, and Foundayo. Insurance concierge handles the paperwork.
Does “FDA-Regulated Facility” Mean the Medication Is FDA-Approved?
No. And this is the single biggest source of confusion in the entire compounded GLP-1 market.
“FDA-regulated” sounds reassuring — compounding pharmacies registered under 503A or 503B operate under FDA regulations. They get inspected. They follow standards. But none of that means the finished medication coming out the door has been individually reviewed and approved by the FDA.
| Concept | What it means | Example |
|---|---|---|
| FDA-regulated facility | The pharmacy is subject to FDA oversight rules | Triad Rx, RedRock, Beaker Pharmacy & Compounding |
| FDA-approved drug | The specific finished medication was reviewed and authorized for marketing for a specific use | Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo |
The translation you actually need:
FDA-regulated facility = the pharmacy is being watched
FDA-approved drug = the medicine was reviewed before it was sold
The second is a higher bar. It’s the bar Wegovy and Zepbound clear. It’s not the bar compounded medications clear.
Is Compounded Semaglutide or Tirzepatide Still Allowed After the Shortages Ended?
It’s narrower than it used to be — and the trajectory is tightening.
| Date | Event |
|---|---|
| Dec. 19, 2024 | FDA declared tirzepatide injection shortage resolved |
| Feb. 21, 2025 | FDA declared semaglutide injection shortage resolved |
| 2025–2026 | FDA tightened enforcement on mass-marketed compounded GLP-1s; multiple warning letters issued, including to MEDVi (#721455, Feb 20, 2026) |
| April 2026 | FDA clarified that adding vitamin B-12 doesn't automatically make a compounded product "personalized" — prescribers must document a patient-specific reason |
| Apr. 30, 2026 | FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; public comments due June 29, 2026 |
The practical takeaway
If you’re choosing a compounded GLP-1 in 2026, you’re making a cash-pay cost decision, not an access-of-last-resort decision. That’s a legitimate choice — but it’s a different choice than it was two years ago. Know that going in.
What Does MEDVi Cost? (Verified Pricing + Cancellation Reality)
MEDVi compounded pricing (verified May 16, 2026)
| Option | First month | Refill price |
|---|---|---|
| Compounded semaglutide injection | $179 | $299 (verified on MEDVi GLP page) |
| Compounded tirzepatide injection | $349 (start) | Confirm at checkout |
| Compounded semaglutide tablet | $249 (start) | Confirm at checkout |
| Compounded tirzepatide tablet | $279 (start) | Confirm at checkout |
MEDVi brand-name pricing (verified May 16, 2026)
| Option | Cost |
|---|---|
| Brand-name Wegovy or Zepbound through MEDVi | $99 membership + medication cost (Wegovy ≈ $1,349, Zepbound ≈ $1,086 list before discounts) |
| Brand-name Ozempic through MEDVi | $1,999/month (MEDVi published price) |
Sources: MEDVi.org, glp.medvi.org, home.medvi.org. Verified May 16, 2026. Verify current pricing at checkout.
Pricing fact #1: The refill jump
Semaglutide goes from $179 to $299 after month one — a 67% increase. Budget for the refill price, not the intro price.
Pricing fact #2: The 72-hour cancellation window
Cancellation requests must be received at least 72 hours before your billing date. Outside of medical disqualification, cancellation does not generate a refund. Read this twice before you enter a credit card.
Verify medication type and cancellation terms before payment.
Can You Use Insurance for MEDVi?
No.
MEDVi is cash-pay only and does not file insurance claims. HSA and FSA funds may be eligible depending on your plan administrator’s rules — keep your receipts and a clinician note if you plan to submit for reimbursement.
| What you need | Where to look |
|---|---|
| Insurance billing handled by the provider | Ro — free Insurance Coverage Checker, insurance concierge service that handles prior authorization paperwork |
| Cash-pay with provider choice and Costco-member pricing | Sesame Care — accepts insurance for some weight-loss medications |
| Use your existing PCP and pharmacy | Your PCP + your pharmacy + manufacturer copay savings |
| HSA/FSA reimbursement on a cash-pay program | MEDVi may work — confirm with your plan administrator first |
See your specific coverage in under two minutes.
What to Ask Before You Click “Pay” (The MEDVi Pre-Checkout Checklist)
Assembled from MEDVi’s own disclosures, the FDA warning letter content, current FDA safety guidance, and the questions real customers wish they’d asked.
Before payment
- 1
Compounded or brand-name?
Confirm whether your prescription will be compounded or an actual FDA-approved brand-name drug (Wegovy, Zepbound, Ozempic).
- 2
Which pharmacy?
Get the name of the specific US-licensed pharmacy that will fill your prescription. MEDVi has named Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding as partners.
- 3
Active ingredient form.
If you're getting compounded semaglutide, confirm it uses semaglutide base, not a salt form. The FDA has flagged compounded products containing salt forms.
- 4
Dose verification.
The FDA has received reports of adverse events related to dosing errors with compounded injectable semaglutide. Confirm your dose, titration schedule, and self-injection instructions in writing.
- 5
First-month price and refill price.
These are different numbers. Know both before paying.
- 6
Annual prepay terms.
If you're considering an annual upfront option, ask what happens if you need to stop mid-year.
- 7
Cancellation window.
MEDVi requires cancellation 72 hours before the next billing cycle. Note the date.
- 8
Refund policy.
Outside of medical disqualification, MEDVi does not refund cancellations. Confirm this in writing.
- 9
State availability.
Confirm your state at checkout.
After your first shipment arrives
- 10
Was it cold?
Injectable GLP-1s need refrigeration. The FDA has received complaints across the compounded GLP-1 market that some shipments arrived warm. Do not use anything that arrived improperly stored — contact MEDVi support.
- 11
Does the medication look consistent?
Compare to your provider's description of the formulation. Cloudy when it should be clear is a flag.
- 12
Is the dispensing pharmacy on the label?
It should be. Match it against the name MEDVi gave you at checkout.
- 13
Did you get clear dosing instructions?
Titration schedules vary. If yours is unclear, message MEDVi before injecting.
Throughout your subscription
- 14
Track your billing dates.
Don't get caught by the 72-hour cancellation window.
- 15
Document your support interactions.
Screenshots and timestamps are your evidence if you need to dispute a charge.
Who MEDVi Actually Fits (And Who It Doesn’t)
MEDVi is a real fit if:
- ✓You're cash-pay and brand-name medication is genuinely out of reach financially
- ✓You've read and accepted that compounded GLP-1s are not FDA-approved finished products
- ✓You want a lower monthly cost on a verified-legitimate platform
- ✓You're comfortable asking pharmacy and medication-source questions
- ✓You can track a 72-hour cancellation window without forgetting
- ✓You have HSA or FSA funds available
MEDVi compounded is NOT for you if:
- ✗You need an FDA-approved finished medication
- ✗You need your insurance to cover the medication
- ✗You're uncomfortable with compounded medications generally
- ✗You have a complex medical history that needs in-person continuity
- ✗You can't tolerate the 72-hour cancellation rule and largely non-refundable billing
The damaging admission
MEDVi’s compounded path does NOT carry FDA-approved finished products. If having an FDA-approved finished drug product is non-negotiable for you, the compounded path is the wrong fit — choose either MEDVi’s own $99 brand-name path or a fully brand-name provider like Ro. That’s the trade-off MEDVi makes. It’s also why MEDVi can deliver compounded semaglutide for $179 the first month.
If FDA Approval Is Non-Negotiable: Where to Look
Path 1: Ro — strong FDA-approved fit for most readers
Ro is built around FDA-approved GLP-1 medications and insurance support. Current formulary:
- →Wegovy® pen — FDA-approved for chronic weight management; cash pay starting at $199/mo for lower doses
- →Wegovy® pill — FDA-approved oral semaglutide (approved Dec. 2025); cash pay $149–$299/mo
- →Zepbound® KwikPen — FDA-approved for chronic weight management & obstructive sleep apnea; starting at $299 first month
- →Foundayo™ (orforglipron) — FDA-approved oral GLP-1 (approved April 2026); cash pay $149–$299/mo
Ro Body membership: $39 first month / $149/month ongoing / as low as $74/month with annual prepay.
- → Free GLP-1 Insurance Coverage Checker
- → Insurance concierge handles prior authorization paperwork
- → Foundayo access (new oral GLP-1 most providers don’t carry yet)
Pricing verified at ro.co on May 16, 2026. Promotional offers can change.
See what your insurance covers in under two minutes. No commitment.
Path 2: Sesame Care — for provider-choice shoppers
Sesame lists Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, and Saxenda. Cash-pay medication starts around $149/month, and Sesame accepts insurance for some weight-loss medications. Costco-member pricing applies to certain medications. Fits if you want to pick the specific clinician you’ll work with, or if you’re a Costco member.
Path 3: Your PCP + your pharmacy
The cheapest FDA-approved path of all, if your insurance covers Wegovy or Zepbound: a primary care visit, a prescription, and a pharmacy fill. With insurance and manufacturer copay savings, Wegovy can run as low as $0 for a 28-day supply for eligible patients. Without insurance, you’re back at $1,000+/month — which is why most people land on Ro or a compounded provider instead.
What Real MEDVi Patients Say (Customer-Experience Themes Only)
Sourced from Trustpilot, ConsumerAffairs, BBB, and Reddit on May 16, 2026. These are customer-experience themes only — they do not establish medical safety or efficacy.
Trustpilot (≈13,000 reviews, TrustScore 4.5/5)
Positive patterns: speed of approval (medication delivery within a week), provider communication (24/7 messaging), and price ($179 first-month entry).
BBB, ConsumerAffairs, Reddit
Most consistent negative pattern: billing and cancellation friction — being charged after attempting to cancel, struggling to get refunds, or missing the 72-hour cancellation deadline. This is consistent with MEDVi’s own published refund policy.
How We Verified This Page
| Claim | Verified against | Date |
|---|---|---|
| MEDVi's compounded GLP-1s are not FDA-approved | MEDVi's own terms and product pages (home.medvi.org) | May 16, 2026 |
| FDA Warning Letter #721455 contents | FDA.gov primary source | May 16, 2026 |
| MEDVi's April 8, 2026 response | MEDVi's official communication page | May 16, 2026 |
| MEDVi compounded semaglutide pricing ($179 / $299) | MEDVi GLP-1 page (glp.medvi.org) | May 16, 2026 |
| MEDVi tirzepatide injection $349 starting | MEDVi product navigation | May 16, 2026 |
| MEDVi semaglutide tablets $249 starting | MEDVi product navigation | May 16, 2026 |
| MEDVi tirzepatide tablets $279 starting | MEDVi product navigation | May 16, 2026 |
| MEDVi Ozempic injection $1,999/month | MEDVi product navigation | May 16, 2026 |
| MEDVi cancellation policy (72-hour rule, generally non-refundable) | MEDVi cancellation and refund policy | May 16, 2026 |
| Ro pricing and formulary | Ro.co pricing and product pages | May 16, 2026 |
| FDA semaglutide shortage resolution (Feb 21, 2025) | FDA Drug Shortage records | May 16, 2026 |
| FDA tirzepatide shortage resolution (Dec 19, 2024) | FDA Drug Shortage records | May 16, 2026 |
| April 30, 2026 FDA 503B bulks-list proposal | FDA press announcement | May 16, 2026 |
| Industry-wide warning letter sweep (30+ companies) | STAT News reporting + FDA Warning Letters database | May 16, 2026 |
| Wegovy pill FDA approval (December 2025) | Novo Nordisk announcement | May 16, 2026 |
| Foundayo (orforglipron) FDA approval (April 1, 2026) | FDA novel drug list | May 16, 2026 |
Last verified: May 16, 2026. We refresh this page monthly.
Bottom Line: Which Path Is Yours?
| Your situation | The best fit | Next step |
|---|---|---|
| “I only want FDA-approved medication, and I want help with insurance.” | Ro | Check Ro’s free Insurance Coverage Checker → |
| “I want FDA-approved medication, and I like the MEDVi platform.” | MEDVi brand-name path ($99 + medication) | See MEDVi’s Wegovy/Zepbound options → |
| “I’m comfortable with compounded after reading this page, and I want the lower cash-pay cost.” | MEDVi compounded path | See MEDVi’s compounded pricing → |
| “I want brand-name with provider choice or Costco pricing.” | Sesame Care | Compare Sesame’s GLP-1 program |
| “I’m still not sure.” | Our 60-second matching quiz | Take the quiz → |
The thing nobody else will tell you: there is no single right answer to “Is MEDVi GLP-1 FDA approved?” — because MEDVi sells two different categories of medication. The right path is the one that matches your priorities. You now know more than most people considering MEDVi do.
No payment info. Personalized fit in under a minute.
Frequently Asked Questions
Is MEDVi semaglutide FDA approved?
No. MEDVi's compounded semaglutide is not FDA-approved as a finished product. Brand-name semaglutide drug products — Wegovy (chronic weight management) and Ozempic (type 2 diabetes) — are FDA-approved for their specific labeled uses. MEDVi's compounded semaglutide is prepared by a compounding pharmacy and has not been individually reviewed by the FDA for safety, effectiveness, or quality.
Is MEDVi tirzepatide FDA approved?
No. Brand-name tirzepatide drug products — Zepbound (chronic weight management & obstructive sleep apnea) and Mounjaro (type 2 diabetes) — are FDA-approved for their specific labeled uses. MEDVi's compounded tirzepatide is not FDA-approved as a finished product.
Does MEDVi sell anything that IS FDA-approved?
Yes. MEDVi offers FDA-approved brand-name Wegovy and Zepbound through a separate $99 membership path. The medication you receive on that path is the same brand-name product manufactured by Novo Nordisk or Eli Lilly, FDA-approved for chronic weight management.
Did MEDVi actually get an FDA warning letter?
Yes. On February 20, 2026, the FDA issued MEDVi Warning Letter #721455 citing misbranding violations on the medvi.io website. The letter addressed marketing claims that the FDA said implied FDA approval or evaluation for safety and effectiveness. It did not directly allege contamination, patient harm, or a defective shipment. MEDVi was one of more than 30 telehealth companies issued similar warning letters in February and March 2026.
Can I use insurance for MEDVi?
No. MEDVi is cash-pay only and does not file insurance claims. HSA and FSA funds may be eligible depending on your plan administrator. If insurance billing is essential, Ro offers a free Insurance Coverage Checker and concierge support that handles prior authorization paperwork.
Does FDA-regulated mean FDA-approved?
No. An FDA-regulated facility is subject to FDA oversight rules. An FDA-approved drug has been individually reviewed for safety, effectiveness, and quality before being authorized for marketing. A medication can come from a regulated facility without being FDA-approved as a finished product.
Are compounded GLP-1 medications legal?
Compounding can be lawful under sections 503A or 503B when all requirements are met, but legality depends on the exact product, the pharmacy, the prescription, shortage status, and the compounding pathway. After the GLP-1 shortages officially resolved (tirzepatide December 2024, semaglutide February 2025), and after the FDA's April 30, 2026 proposal to exclude these drugs from the 503B bulks list, compounded versions face tighter restrictions.
What is MEDVi's cancellation policy?
MEDVi requires cancellation requests at least 72 hours before the next billing date. Outside of medical disqualification, cancellation does not generate a refund. Verify the policy in writing before enrolling.
Are MEDVi's compounded products the same as Wegovy or Ozempic?
No — and we won't describe them that way. The FDA specifically cited 'same active ingredient as Wegovy and Ozempic' as misleading language in MEDVi's warning letter. Wegovy and compounded semaglutide may both involve semaglutide, but they are not the same finished drug product. The compounded version is not FDA-approved and has not been individually evaluated by the FDA for safety, effectiveness, or quality.
Why Trust This Page
We’re not MEDVi. We’re not Ro. We’re not paid to recommend one over the other. Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We do earn a commission when readers enroll through some links on this page — but the commission rate does not change what we publish.
Compounded medications are not FDA-approved no matter who pays us. The February 2026 warning letter is real no matter who pays us. MEDVi’s brand-name path exists no matter who pays us. Our editorial rule: if removing every CTA on a page would make the page worse, the page isn’t ready to publish.
Related guides
- → Switching from MEDVi to Ro: 7-Step Plan
- → Best GLP-1 Telehealth Providers (2026)
- → GLP-1 Telehealth Informed Consent: What You're Agreeing To
- → Who Can Prescribe GLP-1 Medications Online (2026)
- → GLP-1 Telehealth Safety Checklist: 15-Point Vetting Guide
- → Find My GLP-1 Path — personalized provider quiz